Cerus Corporation (CERS)
CERS Price and Sentiment
CERS Latest news
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the
According to the GuruFocus Scoreboard, where users can sort investing gurus based on their fund performances over specific periods of time, the gurus that posted the highest gains during the most recent year were Catherine Wood (Trades, Portfolio) and Ron Baron (Trades, Portfolio). For full-year 2020, Wood's Ark Investment Management returned 152.50%, while Ron Baron (Trades, Portfolio)'s Baron Funds gained 148.50%.
CONCORD, Calif.--(BUSINESS WIRE)--Today marks the effective date for the U.S. Food and Drug Administration's (FDA) final guidance document on bacterial risk control strategies for platelet collection and transfusion. This guidance for industry, “Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelet for Transfusion,” which was finalized in 2020, identifies FDA-approved pathogen reduction as a means of com
Cerus Corporation Announces INTERCEPT Fibrinogen Complex Customer Presentations at SABM Virtual Annual Meeting 20212021-09-20 08:00
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced its participation in the Society for the Advancement of Blood Management (SABM) Virtual Annual Meeting, which is scheduled for September 22-25, 2021. On Thursday, September 23, Cerus will host an industry workshop, “Clinical need for and experience with the new Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex),” from 1:00-1:30p.m. EDT featuring two hospital customers currently us
Cerus Corp.: Record Revenue Warrants A Slight Change In Strategy
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief financial officer, are scheduled to participate in the 2021 Cantor Global Virtual Healthcare Conference on Wednesday, September 29, 2021 at 11:20 a.m. ET. A live webcast of the presentation will be available on Cerus' Investor Relations page at http://www.cerus.com/ir. A replay of the webcast will be availa
Cerus Corporation Announces CMS Issuance of P-Codes for Hospital Outpatient Billing of INTERCEPT-Based Therapeutic Products2021-08-10 08:30
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted permanent Healthcare Common Procedure Coding System (HCPCS) Level II codes for Pathogen Reduced Cryoprecipitated Fibrinogen Complex, or INTERCEPT Fibrinogen Complex (IFC), and Pathogen Reduced Plasma, Cryoprecipitate Reduced. These new P-codes, P9026 and P9025, respectively, are effective October 1, 2021. “By providing a means for hospit
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the appointment of Ann Lucena, CEO of San Ramon Regional Medical Center (SRRMC), to its Board of Directors. SRRMC, a 123-bed acute care hospital located in the East Bay Area, is part of a joint venture involving Tenet Healthcare. She also serves as the chairperson of the board overseeing the joint venture between John Muir Health and San Ramon Regional Medical Center. “We are delighted to welcome Ann to Cerus' Bo
The stock price of Cerus Corporation (NASDAQ: CERS) increased by over 13% pre-market. This is why it happened.
Cerus Corporation (NASDAQ: CERS) reported second-quarter sales of $37.8 million, +41% Y/Y in line with the consensus. Product revenue reached $31.5 million, compared to $21.5 million a year ago, benefited from increased demand for INTERCEPT platelet products in the U.S.